Indication CINRYZE® (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE).
Takeda’s OnePath program offers product support for your eligible HAE patients prescribed a Takeda therapy. Through OnePath, patients are connected with a dedicated Patient Support Manager (PSM) who can assist them with a variety of services, including:
Facilitating an insurance benefits investigation to verify coverage, including working with a Patient Access Manager to address any insurance or access-related issues
Providing information about financial assistance options
Working with specialty pharmacies to facilitate treatment access
Setting up administration training for patients and caregivers, if requested
Informing patients and family members about additional resources available to them
Patients enrolled in OnePath can connect to the OnePath Mobile App at no cost.
For questions about OnePath, call 1-866-888-0660. OnePath is available Monday through Friday from 8:30 am to 8:00 pm ET.
Enrolling in OnePath
1. Sign up
All it takes is for you and your eligible patients to complete the downloadable OnePath Start Form.
2. Patient Support Manager
A Patient Support Manager initiates a benefits investigation and helps provide information about the prior authorization process to your office (if applicable) and financial assistance options (if needed).
3. Product access and support
The Patient Support Manager sets up product shipment with a specialty pharmacy, serves as an ongoing resource for your patients throughout therapy, and coordinates self-administration training for eligible patients through Path to Independence™, a program in which specially trained infusion nurses instruct patients on the specific techniques necessary for self-administration.
Complete the form with your patient and fax it to 1-855-ONEPATH (1-855-663-7284).
Contraindications: CINRYZE is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product.
Hypersensitivity Reactions: Severe hypersensitivity reactions may occur during or after administration of CINRYZE. Consider treatment methods carefully, because hypersensitivity reactions may have symptoms similar to HAE attacks. In case of hypersensitivity, discontinue CINRYZE infusion and institute appropriate treatment. Have epinephrine immediately available for treatment of an acute severe hypersensitivity reaction.
Thromboembolic Events: Serious arterial and venous thromboembolic (TE) events have been reported at the recommended dose of C1 Esterase Inhibitor (Human) products, including CINRYZE, following administration in patients with HAE. Risk factors may include presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives, certain androgens, morbid obesity, and immobility. Benefits of CINRYZE for routine prophylaxis of HAE attacks should be weighed against the risks of TE events in patients with underlying risk factors. Monitor patients with known risk factors for TE events during and after CINRYZE administration.
Transmissible Infectious Agents: Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g. viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ALL infections thought by a physician possibly to have been transmitted by CINRYZE should be reported to Shire Medical Information at 1-800-828-2088.
Adverse Reactions: The only serious adverse reaction observed in clinical studies of CINRYZE was cerebrovascular accident. The most common adverse reactions (≥5%) observed were headache, nausea, rash, vomiting, and fever. Post marketing adverse reactions include local infusion site reactions and hypersensitivity. Post marketing thromboembolic events have been reported, including catheter-related and deep venous thromboses, transient ischemic attack, and stroke.
Please click here for Full Prescribing Information.
To report SUSPECTED ADVERSE REACTIONS, contact Shire Medical Information at 1-800-828-2088 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.